Treatment Advances

Our Treatment Advances articles cover treatment option updates, new combinations of treatments, FDA approval news, and more.

Headlines All Categories Treatment Advances Navigating Your Health Core Education Patient Stories HealthTree Research Conferences Clinical Trials HealthTree Programs HealthTree Press

Recent Articles

Understanding Your Treatment Options After Being Diagnosed with Advanced-Stage Follicular Lymphoma

October 29, 2024

If you are a person with advanced-stage follicular lymphoma who is starting their first treatment, learn how certain therapy options compare.

How One DLBCL Therapy Is Proving Its Worth: Three Years Later

October 15, 2024

After three years since its original Phase III trial, lisocabtagene maraleucel (liso-cel) is still proving effective for relapsed/refractory DLBCL patients.

Large B-Cell Lymphoma with CNS Involvement: Treatment Options and Future Directions

September 16, 2024

Learn about the challenges of treating DLBCL with central nervous system involvement, explore available treatment options, and discover the latest research.

Making CAR-T Therapy Safer and More Accessible for DLBCL Patients

August 29, 2024

CAR-T therapy side effects in DLBCL patients are rare after two weeks, but how long should patients be monitored?

Understanding R-CHOP: A Treatment Option for Follicular Lymphoma

August 13, 2024

Learn about R-CHOP, a chemoimmunotherapy regimen used to treat follicular lymphoma. Understand its effectiveness and what to expect during treatment.

Is Age Just A Number? Analyzing CAR T-cell Therapy for B-cell Lymphoma

July 22, 2024

Is age just a number? Dr. Julio Chavez shares multicenter findings on how CAR T therapy can be effective in those 80 and older.

New Bispecific Antibody AZD0486 for Relapsed/Refractory Lymphoma

July 17, 2024

Discover insights from Dr. Ryan Jacobs on AZD0486, a new bispecific antibody for relapsed or refractory lymphoma patients.

New CAR T-Cell Therapy Approved for MCL

July 05, 2024

A new car t-cell therapy was just approved for relapsed or refractory mantle cell lymphoma patients, sparking hope for those facing this aggressive cancer.